Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

KROSKROS
Showing 8 of 25 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in KEROS THERAPEUTICS INC

CITADEL ADVISORS LLC holds 396,098 shares of KROS (KEROS THERAPEUTICS INC), worth $4.2M as of 2026-Q2. The position was decreased (-2.6% shares). KROS represents 0.0% of CITADEL ADVISORS LLC's portfolio.

Current Value

$4.2M

Current Shares

396,098

Total Value Change

-$36.7M

Total Shares Change

-308,825

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
396,098
-2.6%
$4.2M0.0%$10.70
0
2026-Q1
Decreased
406,666
-13.9%
$4.5M0.0%$13.40
0
2025-Q4
Increased
472,520
+168.3%
$9.6M0.0%$20.27
45
2025-Q3
Increased
176,144
+669.3%
$2.8M0.0%$15.95
42
2025-Q2
Decreased
22,898
-88.0%
$305,6880.0%$13.49
0
2025-Q1
Decreased
191,609
-75.8%
$2M0.0%$10.79
0
2024-Q4
Increased
791,109
+12.2%
$12.5M0.0%$15.64
31
2024-Q3
Increased
704,923
+71.7%
$40.9M0.0%$56.45
43

Other major holders of KROS: BlackRock Finance, Inc., RA CAPITAL MANAGEMENT, L.P., ALKEON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used